List of Akebia Therapeutics patents

Patents where

Current Assignee

Name

Akebia Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10246416 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides	Patent 10246416 was granted and assigned to Akebia Therapeutics on April, 2019 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	10246416	April 2, 2019
‌ US Patent 11267785 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides	Patent 11267785 was granted and assigned to Akebia Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	11267785	March 8, 2022
‌ US Patent 9776969 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides	Patent 9776969 was granted and assigned to Akebia Therapeutics on October, 2017 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	9776969	October 3, 2017
‌ US Patent 9145366 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides	Patent 9145366 was granted and assigned to Akebia Therapeutics on September, 2015 by the United States Patent and Trademark Office.		Akebia Therapeutics	United States Patent and Trademark Office	9145366	September 29, 2015
‌ US Patent 11426393 Prolyl hydroxylase inhibitors and methods of use	Patent 11426393 was granted and assigned to Akebia Therapeutics on August, 2022 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	11426393	August 30, 2022
‌ US Patent 10149842 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof	Patent 10149842 was granted and assigned to Akebia Therapeutics on December, 2018 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	10149842	December 11, 2018
‌ US Patent RE47437 Prolyl hydroxylase inhibitors and methods of use	Patent RE47437 was granted and assigned to Akebia Therapeutics on June, 2019 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	RE47437	June 18, 2019
‌ US Patent 8722895 Prolyl hydroxylase inhibitors and method of use	Patent 8722895 was granted and assigned to Akebia Therapeutics on May, 2014 by the United States Patent and Trademark Office.		Akebia Therapeutics	United States Patent and Trademark Office	8722895	May 13, 2014
‌ US Patent 8940773 Prolyl hydroxylase inhibitors and methods of use	Patent 8940773 was granted and assigned to Akebia Therapeutics on January, 2015 by the United States Patent and Trademark Office.		Akebia Therapeutics	United States Patent and Trademark Office	8940773	January 27, 2015
‌ US Patent 11065237 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof	Patent 11065237 was granted and assigned to Akebia Therapeutics on July, 2021 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	11065237	July 20, 2021
‌ US Patent 9701636 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof	Patent 9701636 was granted and assigned to Akebia Therapeutics on July, 2017 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	9701636	July 11, 2017
‌ US Patent 9598370 Prolyl hydroxylase inhibitors and methods of use	Patent 9598370 was granted and assigned to Akebia Therapeutics on March, 2017 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	9598370	March 21, 2017
‌ US Patent 9987262 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof	Patent 9987262 was granted and assigned to Akebia Therapeutics on June, 2018 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	9987262	June 5, 2018
‌ US Patent 11324734 Compositions and methods for treating anemia		Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	11324734	May 10, 2022
‌ US Patent 10150734 Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof	Patent 10150734 was granted and assigned to Akebia Therapeutics on December, 2018 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	10150734	December 11, 2018
‌ US Patent 10729681 Prolyl hydroxylase inhibitors and methods of use	Patent 10729681 was granted and assigned to Akebia Therapeutics on August, 2020 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	10729681	August 4, 2020
‌ US Patent 10738010 Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides	Patent 10738010 was granted and assigned to Akebia Therapeutics on August, 2020 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	10738010	August 11, 2020
‌ US Patent 11524939 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid		Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	11524939	December 13, 2022
‌ US Patent 10596158 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof	Patent 10596158 was granted and assigned to Akebia Therapeutics on March, 2020 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	10596158	March 24, 2020
‌ US Patent 8865748 Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer	Patent 8865748 was granted and assigned to Akebia Therapeutics on October, 2014 by the United States Patent and Trademark Office.		Akebia Therapeutics	United States Patent and Trademark Office	8865748	October 21, 2014
‌ US Patent 11713298 Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid		Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	11713298	August 1, 2023
‌ US Patent 11883386 Prolyl hydroxylase inhibitors and methods of use	Patent 11883386 was granted and assigned to Akebia Therapeutics on January, 2024 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	11883386	January 30, 2024
‌ US Patent 11857543 Compositions and methods for treating anemia	Patent 11857543 was granted and assigned to Akebia Therapeutics on January, 2024 by the United States Patent and Trademark Office.	Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	11857543	January 2, 2024
‌ US Patent 11690836 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof		Akebia Therapeutics	Akebia Therapeutics	United States Patent and Trademark Office	11690836	July 4, 2023

24 results

0 selected

24 results

0 selected